相关实验视频

Updated: Jun 29, 2025

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Author Spotlight: Studying Host-Virus Interactions with Pseudotyped Viruses

Published on: November 21, 2023

莫尔努皮拉维尔对免疫受损患者SARS-CoV-2演变的影响:一项回顾性观察性研究

Nicholas M Fountain-Jones¹, Robert Vanhaeften², Jan Williamson²

¹Pathology Department, Royal Hobart Hospital, Hobart, TAS, Australia; School of Natural Sciences, University of Tasmania, Hobart, TAS, Australia.

The Lancet. Microbe

|March 25, 2024

概括

在长期感染SARS-CoV-2的免疫功能低下患者中,molnupiravir治疗增加了病毒突变. 这表明新型变种出现和传播超出标准治疗持续时间的可能性.

科学领域:

病毒学病毒学
基因组学就是基因组学.
免疫学免疫学免疫学

背景情况:

长时间的SARS-CoV-2感染在免疫受损的个体可以推动病毒的进化和变种的出现.
莫尔努皮拉维尔是一种用于COVID-19的抗病毒药物,但其对慢性感染中的病毒演变的长期影响尚不清楚.

研究的目的:

为了研究molnupiravir对SARS-CoV-2在长期感染的免疫功能低下患者的演变的影响.
为了比较molnupiravir治疗和未治疗患者之间的病毒突变概况.

主要方法:

从用molnupiravir和对照组治疗的免疫功能低下患者的病毒基因组测序.
随着时间的推移使用生物信息管道分析突变概况和变异频率.
突变模式与全球SARS-CoV-2变种的比较.

主要成果:

莫尔努皮拉维尔治疗导致10天内病毒变异的低至中频率显著增加.
一些变异,包括尖端蛋白突变,在病毒群体中变得固定.
一个独特的突变特征 (G-to-A,C-to-T) 主导治疗患者,持续治疗后长达44天.

结论:

摩尔努皮拉维尔治疗诱导了SARS-CoV-2的独特突变模式,超出了推的治疗过程.
接受治疗的患者表现出持续的PCR阳性,突出显示了传播和新型变异生成的风险.

更多相关视频

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Humanized NOD/SCID/IL2rγ^null (hu-NSG) Mouse Model for HIV Replication and Latency Studies

Published on: January 7, 2019

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Reverse Genetics to Engineer Positive-Sense RNA Virus Variants

Published on: June 9, 2022

相关概念视频

Viral Mutations

Viral Mutations

A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...